| Lung Non-Small Cell Carcinoma with Genetic Abnormalities studied in …STUDIED_INderived31 of 31show fewer |
|---|
| → studied in | NCT05987956Phase 2/Phase 3 · active not recruiting Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834074available Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07617337Phase 1 · recruiting AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393625Phase 1 · active not recruiting Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07567352active not recruiting A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07491497Phase 1/Phase 2 · recruiting A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06797362available Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ROS1-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07784959Phase 1 · recruiting Study of NXP900 With Lorlatinib in ALK+ Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07771764Phase 2 · not yet recruiting A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750704Phase 2 · not yet recruiting Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07633626recruiting Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841874no longer available Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ROS1-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04900935NA · recruiting Patient-centered, Optimal Integration of Survivorship and Palliative Care · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06846736enrolling by invitation ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785584Phase 4 · not yet recruiting Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06410040unknown A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04211922Phase 2 · terminated Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06361589recruiting Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04979988completed Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06092086Phase 2 · recruiting Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647110completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02513667Phase 2 · terminated Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482087Phase 2 · unknown A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03131206Phase 1/Phase 2 · terminated A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02893332Phase 3 · terminated Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) · condition mapped CURATED_BROADER · 31 trials mapped (14 active) | — | — | Lung Non-Small Cell Carcinoma with EGFR Mutation | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04203485Phase 3 · unknown Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | PD-L1-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02336451Phase 2 · completed A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04009317Phase 3 · unknown Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04056572Phase 2 · unknown Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03972189Phase 2 · unknown Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) · condition mapped ALIAS · 31 trials mapped (14 active) | — | — | ROS1-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02258607Phase 1 · terminated Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase · condition mapped CURATED_BROADER · 31 trials mapped (14 active) | — | — | Lung Non-Small Cell Carcinoma with KRAS Mutation | 1 | Observed | clinicaltrials | graph → |